IO Biotech, Inc. — Director's Dealing 2021

Nov 5, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: IO Biotech, Inc. (IOBT)
CIK: 0001865494
Period of Report: 2021-11-04

Reporting Person: Lundbeckfond Invest A/S (N/A)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Preferred Stock	$		Common Stock (2014161)		Direct
Series C Preferred Stock	$		Common Stock (1892434)		Direct

Footnotes

F1: Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series B Preferred Stock beneficially owned by the reporting person will automatically convert, for no additional consideration, into the number of shares of Common Stock reported in Column 3. These shares of Series B Preferred Stock have no expiration date.

F2: Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series C Preferred Stock beneficially owned by the reporting person will automatically convert, for no additional consideration, into the number of shares of Common Stock reported in Column 3. These shares of Series C Preferred Stock have no expiration date.